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Joseph T. Knapper, MD,* Gregory R. Hartlage, MD,y Stephen D. Clements, MDyA n 89-year-old woman was admitted to thehospital with dyspnea, renal failure, andatrial ﬁbrillation with rapid ventricularFIGURE 1 Pre- and Post-BMV Evaluation of Severe Non-Rheumatic M
(A) TTE (parasternal long-axis view) showing proximal ﬂow convergenc
view) demonstrating severe calciﬁcation of both mitral leaﬂets and the m
diastole (Online Video 2). (C) TEE (mid-esophageal view, diastole) with 3
mobility and reduced valve area (Online Video 3). (D) Continuous-wave D
of 22 mm Hg. (E) Inﬂation of a 26-ml Inoue balloon within the stenotic
Doppler from post-procedural TTE demonstrates a mitral valve gradient
echocardiogram; TTE ¼ transthoracic echocardiogram.
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e168annular calciﬁcation (MAC), calciﬁcation of the leaﬂet
bases, and shortening of the subvalvular apparatus—
all consistent with severe nonrheumatic mitral steno-
sis (MS). Mean gradient was 18 to 22 mm Hg, with a
valve area of 0.7 to 0.9 cm2 by pressure half-time.
Attempts were made to improve her low-output
state, but intermittent hypotension limited beta-
blocker up-titration, and atrioventricular nodal abla-
tion with VVI pacing at 55 beats/min provided no
clinical beneﬁt. Her comorbid conditions precluded
surgical valve intervention. After extensive discus-
sion with family, the decision was made to pursue
balloon mitral valvuloplasty (BMV) despite her un-
favorable valve anatomy.
Transfemoral BMV was performed using a 26-ml
Inoue balloon (Toray, Tokyo, Japan) (Figure 1E,
Online Videos 4 and 5). Following balloon inﬂation,
systolic blood pressures rapidly increased from the
90s to the 130s. Intraprocedural echocardiogram
showed a decrease in the mean gradient from 22
to 9 mm Hg (Figure 1F), with no increase in mitralregurgitation. Her symptoms signiﬁcantly improved,
and after several days of physical therapy, the patient
walked out of the hospital under her own power. She
died the following month in home hospice care.
This is the second reported case of BMV in non-
rheumatic MS (1), and the ﬁrst via the transfemoral
approach. BMV is typically avoided because of prior
research suggesting that calciﬁcation is linked to
worse outcomes in rheumatic MS (2). Though such
hesitation is understandable, this case suggests that
BMV may be an option for palliative treatment in poor
surgical candidates with severe nonrheumatic MS.
Transcatheter mitral valve replacement may provide
more durable results (3,4) and should be an area for
future research.
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